LLY

1,036.18

+2.87%↑

JNJ

229.51

-0.3%↓

ABBV

213.69

+0.74%↑

UNH

384.82

-0.13%↓

AZN

187.88

+0.18%↑

LLY

1,036.18

+2.87%↑

JNJ

229.51

-0.3%↓

ABBV

213.69

+0.74%↑

UNH

384.82

-0.13%↓

AZN

187.88

+0.18%↑

LLY

1,036.18

+2.87%↑

JNJ

229.51

-0.3%↓

ABBV

213.69

+0.74%↑

UNH

384.82

-0.13%↓

AZN

187.88

+0.18%↑

LLY

1,036.18

+2.87%↑

JNJ

229.51

-0.3%↓

ABBV

213.69

+0.74%↑

UNH

384.82

-0.13%↓

AZN

187.88

+0.18%↑

LLY

1,036.18

+2.87%↑

JNJ

229.51

-0.3%↓

ABBV

213.69

+0.74%↑

UNH

384.82

-0.13%↓

AZN

187.88

+0.18%↑

Начало・Списък с акции・Anavex Life Sciences Corp
Search

Anavex Life Sciences Corp

Отворен

СекторЗдравеопазване

2.71

Купи

Обновена цена 21.05.2026 г., 14:51 ч. UTC

КупиПродай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.67

Максимум

2.74

Ключови измерители

By Trading Economics

Приходи

4.1M

-5.7M

Служители

34

EBITDA

3.1M

-6.8M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+627.27% upside

Дивиденти

By Dow Jones

Следващи печалби

26.05.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-122M

267M

Предишно отваряне

2.71

Предишно затваряне

2.71

Настроения в новините

By Acuity

50%

50%

159 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

8.275 / 9.312 Подкрепа & съпротива

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.05.2026 г., 23:31 ч. UTC

Горещи акции

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

DJ

Прочетени

20.05.2026 г., 22:52 ч. UTC

Значими двигатели на пазара

Osisko Shares Fall on Planned Convertible Notes Offering

DJ

Прочетени

20.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

DJ

Прочетени

20.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

DJ

Прочетени

20.05.2026 г., 23:44 ч. UTC

Печалби

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

DJ

Прочетени

20.05.2026 г., 23:35 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

DJ

Прочетени

20.05.2026 г., 23:30 ч. UTC

Пазарно говорене

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

DJ

Прочетени

20.05.2026 г., 23:17 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

DJ

Прочетени

20.05.2026 г., 23:17 ч. UTC

Пазарно говорене

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

DJ

Прочетени

20.05.2026 г., 23:15 ч. UTC

Пазарно говорене

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

DJ

Прочетени

20.05.2026 г., 23:14 ч. UTC

Печалби

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

DJ

Прочетени

20.05.2026 г., 23:02 ч. UTC

Пазарно говорене

KMD Brands Faces Two Testing Hurdles -- Market Talk

DJ

Прочетени

20.05.2026 г., 22:57 ч. UTC

Пазарно говорене

Infratil's Other Assets Deserve Attention, Too -- Market Talk

DJ

Прочетени

20.05.2026 г., 22:57 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

DJ

Прочетени

20.05.2026 г., 22:57 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

DJ

Прочетени

20.05.2026 г., 22:51 ч. UTC

Пазарно говорене

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

DJ

Прочетени

20.05.2026 г., 22:51 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

DJ

Прочетени

20.05.2026 г., 22:27 ч. UTC

Пазарно говорене

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

DJ

Прочетени

20.05.2026 г., 22:14 ч. UTC

Пазарно говорене

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

DJ

Прочетени

20.05.2026 г., 22:10 ч. UTC

Печалби

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

DJ

Прочетени

20.05.2026 г., 22:00 ч. UTC

Печалби

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

DJ

Прочетени

20.05.2026 г., 21:38 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

DJ

Прочетени

20.05.2026 г., 21:27 ч. UTC

Печалби

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

DJ

Прочетени

20.05.2026 г., 21:20 ч. UTC

Печалби

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

DJ

Прочетени

20.05.2026 г., 21:19 ч. UTC

Печалби

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

DJ

Прочетени

20.05.2026 г., 21:18 ч. UTC

Печалби

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

DJ

Прочетени

20.05.2026 г., 21:17 ч. UTC

Печалби

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

DJ

Прочетени

20.05.2026 г., 21:17 ч. UTC

Печалби

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

DJ

Прочетени

20.05.2026 г., 21:17 ч. UTC

Печалби

Nvidia's Vera CPU Opens New $200B Market, CFO Says

DJ

Прочетени

20.05.2026 г., 21:16 ч. UTC

Печалби

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

DJ

Прочетени

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

627.27% нагоре

12-месечна прогноза

Среден 20 USD  627.27%

Висок 20 USD

Нисък 20 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

2

Купи

0

Задържане

0

Продай

Според 2 анализатори, дали борсови рейтинги на Anavex Life Sciences Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Средносрочен план

Weak Bullish Evidence

Recent bullish events outweigh bearish events.

Дългосрочен план

Neutral Evidence

The bullish and bearish events are balanced.

Настроение

By Acuity

159 / 345 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Други акции от сектора

LLY

Eli Lilly and Co.

1,036.18

↑ +2.87%

JNJ

Johnson and Johnson

229.51

↓-0.3%

ABBV

AbbVie Inc

213.69

↑ +0.74%

UNH

UnitedHealth Group Inc

384.82

↓-0.13%

AZN

AstraZeneca PLC

187.88

↑ +0.18%
help-icon Live chat